Recent 8-K filings for NRIX

• July 9, 2026, 4:09 PM ET M&A materiality 0.90 positive item 2.02item 9.01

  Nurix enters $2.3B Roche collaboration for bexobrutideg; Q2 net loss $89.5M

  Global collaboration with Roche for bexobrutideg: $700M upfront, up to $2.3B total; co-dev/co-commercialization in hematology, immunology, neurology.

• June 11, 2026, 7:06 AM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Nurix reports Phase 1a/1b data for bexobrutideg: ORR 83% in R/R CLL, 92.9% in earlier-line

  Phase 1a ORR 83.0% (47 evaluable), median PFS 22.1 months; median 4 prior lines.

• June 8, 2026, 6:11 AM ET other material materiality 0.90 positive item 1.01item 7.01item 9.01 ◈ Material Agreements

  Nurix receives $700M upfront from Roche to co-develop BTK degrader bexobrutideg; potential $2.3B total

  Upfront cash payment of $700 million; potential development, regulatory and sales milestones up to $2.3 billion total.

• May 15, 2026, 4:03 PM ET other materiality 0.15 neutral item 5.07item 9.01 ◈ Shareholder Votes ×3

  Nurix Therapeutics 2026 annual meeting votes: directors elected, auditor ratified, say-on-pay approved

  Elected all three Class III director nominees: Arthur T. Sands (63.6M for, 16.3M withheld), Roger Dansey (79.6M for, 0.3M withheld), Paul M. Silva (59.3M for, 20.6M withheld).

• April 8, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Nurix Q1 net loss $87.2M ($0.79); advancing bexobrutideg registrational program

  Revenue $6.3M vs $18.5M YoY; net loss $87.2M ($0.79) vs $56.4M ($0.67).

• March 6, 2026, 6:59 PM ET other material materiality 0.55 neutral item 8.01item 9.01

  Nurix Therapeutics ups ATM equity offering capacity to $413.65M

  Amendment No. 3 to Equity Distribution Agreement with Piper Sandler dated March 6, 2026.

• January 28, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Nurix reports FY2025 net loss of $264.5M; initiates DAYBreak registrational program for bexobrutideg

  FY2025 revenue $84.0M (+54% YoY); net loss $264.5M ($3.05/sh) vs $193.6M ($2.88/sh) last year.

• January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  Nurix outlines bexobrutideg pivotal CLL plan, 83% ORR, $664M cash at JPM

  Phase 2 DAYBreak CLL-201 enrolled Oct 2025; confirmatory Phase 3 vs pirtobrutinib planned in 2026.

• December 9, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Nurix releases Phase 1 CLL/SLL data: 83% ORR, 22.1mo PFS; WM ORR 75.0% at ASH 2025

  Phase 1a CLL/SLL ORR 83.0% (47 evaluable), including 4.3% complete responses; median PFS 22.1 months, DOR 20.1 months.

• November 10, 2025, 6:59 PM ET leadership materiality 0.55 positive item 5.02item 9.01

  Nurix appoints former Pfizer oncology chief Roger Dansey to board

  Dr. Dansey appointed effective Nov 6, 2025, as Class III director and member of Clinical and Commercialization Committee.

• October 22, 2025, 7:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  Nurix raises $250M in registered offering; shares priced at $10.21

  Offering of 24,485,799 shares at $10.21/share; gross proceeds $250.0M, net ~$234.3M.

• October 22, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Nurix initiates pivotal Phase 2 DAYBreak trial of bexobrutideg in r/r CLL with 600 mg QD dose

  DAYBreak Phase 2 will enroll ~100 r/r CLL/SLL patients after prior cBTKi, ncBTKi, and BCL-2i; primary endpoint is ORR by IRC.

• October 9, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Nurix Q3 FY2025 net loss $86.4M ($1.03/share); cash $428.8M; bexobrutideg pivotal trials on track

  Revenue $7.9M vs $12.6M YoY; net loss $86.4M ($1.03/sh) vs $49.0M ($0.67/sh) YoY.

• September 3, 2025, 7:59 PM ET other material materiality 0.65 neutral item 7.01item 9.01

  Nurix begins investor meetings with updated clinical plans for bexobrutideg Phase 1 trial

  Company presenting updated development plans for bexobrutideg (NX-5948), an oral BTK degrader.

• August 22, 2025, 7:59 PM ET leadership materiality 0.20 neutral item 5.02

  Nurix director Lori Kunkel resigns; Roy Baynes named committee chair

  Director Lori A. Kunkel, M.D. resigns from Board and committees effective September 1, 2025.

• July 9, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Nurix Q2 FY2025 revenue $44.1M (+264% YoY); Sanofi extends STAT6 license; bexobrutideg 80.9% ORR in CLL

  Revenue $44.1M (vs $12.1M YoY) driven by $30M Sanofi license extensions and $5M Gilead milestone.

• June 12, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01item 8.01item 9.01

  Nurix bexobrutideg shows 80.9% ORR in CLL, 84.2% in WM; pivotal trials on track for 2025

  ORR 80.9% in CLL/SLL (n=47 evaluable); median time to first response 1.9 months; one complete response after >2 years.

• May 19, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07item 9.01

  Nurix Therapeutics annual meeting elects directors, ratifies auditor, passes say-on-pay

  All three Class II director nominees elected: Reinsdorf (43.57M for), Saltzman (50.30M for), Baynes (60.82M for).

• April 8, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Nurix posts Q1 FY2025 net loss $56.4M; bexobrutideg gets orphan drug designation

  Revenue $18.5M, up from $16.6M YoY; net loss $56.4M ($0.67/share) vs $41.5M prior year.

• March 13, 2025, 7:59 PM ET leadership materiality 0.55 positive item 5.02item 9.01

  Nurix appoints former Merck CMO Roy Baynes to board of directors

  Appoints Roy D. Baynes (EVP & CMO of Eikon, former Merck CMO) as Class II director, effective March 11, 2025.

• January 28, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Nurix Therapeutics reports FY2024 net loss $193.6M, cash $609.6M; NX-5948 ORR 75.5%

  Revenue of $54.5M in FY2024, down from $77.0M YoY; net loss $193.6M ($2.88/share) vs $143.9M ($2.65) prior year.

• January 13, 2025, 6:59 PM ET other material materiality 0.75 positive item 2.02item 7.01item 9.01

  Nurix reports preliminary cash $609.6M; plans pivotal CLL trials for NX-5948 in 2025

  Preliminary cash and investments $609.6M as of Nov 30, 2024; runway into H1 2027.

• December 10, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Nurix: NX-5948 Phase 1 CLL/SLL shows 75.5% ORR, deepens to 84.2%; safe; pivotal trials in 2025

  ORR 75.5% (n=49) in heavily pretreated CLL/SLL; 84.2% in patients with at least 2 assessments.

• October 31, 2024, 7:59 PM ET other material materiality 0.55 neutral item 8.01item 9.01

  Nurix Therapeutics files $300M at-the-market stock offering via Piper Sandler

  Amendment No.2 to Equity Distribution Agreement authorizes up to $300M aggregate gross offering price of common stock in ATM offerings.

• October 16, 2024, 7:59 PM ET leadership materiality 0.35 positive item 5.02item 9.01 ◈ executive_change

  Nurix appoints drug commercialization veteran Anil Kapur to board of directors

  Appointed Anil Kapur as Class I director effective Oct 15, 2024, with term expiring at 2027 annual meeting.

• October 11, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Nurix Therapeutics reports Q3 FY2024 net loss $49M, $0.67 per share; cash $457.5M

  Net loss $49.0M ($0.67 per share) vs $37.0M ($0.68 per share) in Q3 FY2023.

• September 5, 2024, 7:59 PM ET other material materiality 0.50 neutral item 7.01item 9.01

  Nurix to present updated Phase 1 NX-5948 data at investor meetings starting Sept 5

  Company began investor roadshow on September 5, 2024, with an updated investor slide deck.

• July 11, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 8.01item 9.01

  Nurix posts Q2 net loss $44.5M; cash rises to $452.5M; NX-5948 ORR 69.2% in CLL

  Net loss $44.5M ($0.71/sh) vs $24.3M ($0.45/sh) YoY; collaboration revenue $12.1M (+13% YoY).

• June 17, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Nurix Therapeutics: NX-5948 achieves 69.2% ORR in Phase 1 CLL; pivotal trial planned for 2025

  Objective response rate of 69.2% in 26 evaluable CLL patients across 50-600 mg daily doses; responses deepened over time.

• May 21, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07item 9.01

  Nurix Therapeutics annual meeting: stockholders elect directors, ratify auditor, approve say-on-pay

  Stockholders elected directors Julia P. Gregory (29.9M for, 4.5M withheld) and David L. Lacey (27.1M for, 7.3M withheld) to terms expiring 2027.

• April 12, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Nurix prices upsized $175M public offering of 10.17M shares and prefunded warrants at $15.00/share

  10,166,667 common shares at $15.00/share plus 1,500,100 pre-funded warrants at $14.999/warrant.

• April 10, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Nurix Therapeutics Q1 FY2024 revenue $16.6M, net loss $41.5M; Gilead collaboration extended

  Revenue $16.6M (up 31% YoY); net loss $41.5M ($0.76/sh) vs $40.7M ($0.75/sh) prior year.

• April 9, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Nurix announces first clinical responses in brain for BTK degrader NX-5948

  NX-5948 detected in CSF from all available samples, showing brain penetration.

• March 11, 2024, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  FDA lifts partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment to resume

  FDA cleared new chirally controlled NX-2127 drug product; partial hold lifted March 11, 2024.

• February 15, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Nurix FY2023 revenue $77.0M, net loss $143.9M; NX-5948 Fast Track, NX-2127 partial hold

  FY2023 revenue $77.0M (up from $38.6M), net loss $143.9M ($2.65/share) vs $180.4M ($3.71) prior year.

• January 8, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01item 9.01

  Nurix Therapeutics outlines 2024 priorities: BTK degrader NX-5948 acceleration, partial hold on NX-2127

  Positive Phase 1 data for NX-5948 (BTK degrader) in CLL/NHL; plans to accelerate enrollment toward pivotal trials.

• December 11, 2023, 6:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Nurix reports positive Phase 1 data for BTK degraders NX-5948 and NX-2127 at ASH 2023

  NX-5948: 3 partial responses in CLL (n=7); no DLTs or treatment-related SAEs across 50-450 mg doses.

• November 13, 2023, 6:59 PM ET other material materiality 0.50 neutral item 7.01item 9.01

  Nurix presents updated clinical guidance, NX-2127 Phase 1 details

  Investor presentation includes updated guidance on clinical programs.

• November 1, 2023, 7:59 PM ET regulatory materiality 0.75 negative item 8.01item 9.01

  FDA places partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment paused

  FDA partial clinical hold on U.S. Phase 1 study NX-2127-001 for B-cell malignancies; screening and enrollment paused.

• October 12, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Nurix Q3 FY2023 revenue $18.5M, net loss $37.0M; Seagen collaboration yields $60M upfront

  Revenue of $18.5M, up 71% YoY, driven by $8M in research milestones from Gilead and Sanofi.

• September 7, 2023, 7:59 PM ET other material materiality 0.90 positive item 1.01 ◈ Material Agreements

  Nurix signs $60M upfront, $3.4B milestone deal with Seagen for DAC cancer drugs

  Nurix will use DELigase platform to develop protein degraders for conjugation to antibodies by Seagen.

• July 13, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Nurix Q2 net loss narrows to $24.3M ($0.45/sh) on $30.7M revenue; Gilead pays $20M for IRAK4 license

  Net loss of $24.3M ($0.45 EPS) vs $45.4M ($1.01 EPS) in prior year; revenue $30.7M vs $11.4M.

• May 4, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

  Nurix shareholders elect all director nominees; say-on-pay passes with 58.5% support

  All three Class III directors elected: Sands (97.1%), Kunkel (87.5%), Silva (86.2%) of votes cast.

• April 13, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Nurix licenses IRAK4 degrader to Gilead for $20M; Q1 net loss $40.7M

  Gilead exercised option to license NX-0479/GS-6791, triggering $20M payment; up to $425M in milestones plus tiered royalties up to low double-digits.

• April 10, 2023, 7:59 PM ET leadership materiality 0.60 negative item 5.02 ◈ executive_change

  Nurix Therapeutics COO Stefani A. Wolff resigns, effective May 2, 2023

  Stefani A. Wolff notified resignation as COO and EVP of Product Development on April 5, 2023.

• March 13, 2023, 7:59 PM ET other material materiality 0.15 neutral item 8.01

  Nurix Therapeutics discloses minimal SVB exposure; less than 1% of cash at SVB

  SVB closed by California DFPI on March 10; FDIC appointed receiver.

• February 9, 2023, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Nurix reports FY2022 net loss $180.4M, cash $373M; NX-2127 shows clinical benefit in CLL

  Net loss for FY ended Nov 30, 2022: $180.4M ($3.71/shr) vs $117.2M ($2.73/shr) in FY2021; R&D expense $184.5M.

• January 9, 2023, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Nurix Therapeutics outlines 2023 clinical milestones for BTK degraders and CBL-B inhibitor at JPM Conference

  NX-2127 BTK degrader: clinical update and regulatory strategy in H2 2023.

• December 16, 2022, 6:59 PM ET other materiality 0.30 neutral item 5.03item 9.01 ◈ Governance Changes

  Nurix amends bylaws to comply with new universal proxy rules and DGCL updates

  Revised advance notice bylaws require additional disclosures from nominating stockholders and restrict number of nominees to directors up for election.

• December 13, 2022, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Nurix reports positive Phase 1 data for BTK degrader NX-2127; 33% ORR in heavily pretreated CLL

  ORR of 33% (95% CI 12-62%) in 23 CLL patients who failed median 5 prior therapies, 78% prior BTK+BCL2 inhibitors.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event other_material

26 positive 2 negative 22 neutral

source · NRIX on sec.gov